Online citations, reference lists, and bibliographies.
← Back to Search

Second-line Gemcitabine-based Chemotherapy Regimens Improve Overall 3-year Survival Rate In Patients With Malignant Pleural Mesothelioma: A Multicenter Retrospective Study

H. Mutlu, Ş. Gündüz, H. Karaca, Abdullah Büyükçelik, Yasemin Benderli Cihan, A. Erden, Zeki Akça, H. Çoşkun
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Acibadem Kayseri Hospital, Kayseri Training and Research Hospital, and Erciyes University were analyzed and evaluated retrospectively as two groups: second-line gemcitabine-based chemotherapy and no second-line chemotherapy. The median OS of patients who received second-line gemcitabine-based chemotherapy was 11.3 (5.1–17.5) months, while it was 9.9 (2.1–17.7) months in the patients who did not receive chemotherapy in the second-line setting (p = 0.056). When we evaluated the survival rate at the 6th, 12th, 18th, 24th, and 36th month, the OS rate of the 36th month was significantly higher in patients who received gemcitabine-based second-line chemotherapy (p = 0.041). When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5–24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0–17.1) months supportive care after first-line pemetrexed-based regimens (p = 0.005). According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM.
This paper references
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study
Ioannis S Tourkantonis (2011)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Mesothelioma: a review.
F. Mott (2012)
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
Associazione Italiana pneumologi ospedalieri thoracic oncology study group. Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma
L Portalone (2005)
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)
J. Margery (2010)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
G. Utkan (2006)
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
H. Mutlu (2013)
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
J. Margery (2010)
AJCC Cancer Staging Manual
M. B. Amin (2002)
an observational study
A Xanthopoulos (2014)
Ceresoli GL Garassino I De Vincenzo F Cavina R Campagnoli E Zucali PA (2014)
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy
G. Toyokawa (2013)
Epirubicin and Gemcitabine as First-Line Treatment in Malignant Pleural Mesothelioma
L. Portalone (2005)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
A. Xanthopoulos (2008)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar